Sangamo Therapeutics Inc Asset Resilience Ratio
Sangamo Therapeutics Inc asset resilience ratio. Sangamo Therapeutics Inc (SGMO) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SGMO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sangamo Therapeutics Inc (1999–2024)
Asset resilience ratio of Sangamo Therapeutics Inc from 1999 to 2024. This chart shows how Sangamo Therapeutics Inc's Asset Resilience Ratio has changed over time. Read SGMO total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sangamo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SGMO total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sangamo Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Sangamo Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sangamo Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Sangamo Therapeutics Inc Asset Resilience Ratio by Year (1999–2024)
Sangamo Therapeutics Inc asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Sangamo Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $101.64 Million | -- |
| 2023-12-31 | 21.65% | $35.80 Million | $165.32 Million | -9.85pp |
| 2022-12-31 | 31.50% | $177.19 Million | $562.51 Million | +4.12pp |
| 2021-12-31 | 27.38% | $197.68 Million | $721.92 Million | -26.97pp |
| 2020-12-31 | 54.35% | $510.09 Million | $938.55 Million | +10.11pp |
| 2019-12-31 | 44.24% | $282.05 Million | $637.52 Million | +0.25pp |
| 2018-12-31 | 43.99% | $259.71 Million | $590.39 Million | -23.49pp |
| 2017-12-31 | 67.48% | $193.48 Million | $286.74 Million | -8.83pp |
| 2016-12-31 | 76.30% | $120.47 Million | $157.89 Million | +12.08pp |
| 2015-12-31 | 64.22% | $139.52 Million | $217.24 Million | -6.88pp |
| 2014-12-31 | 71.10% | $172.93 Million | $243.21 Million | +12.44pp |
| 2013-12-31 | 58.67% | $82.63 Million | $140.84 Million | +7.94pp |
| 2012-12-31 | 50.73% | $41.87 Million | $82.53 Million | -26.41pp |
| 2011-12-31 | 77.13% | $67.37 Million | $87.34 Million | -1.44pp |
| 2010-12-31 | 78.57% | $49.50 Million | $63.00 Million | +5.63pp |
| 2009-12-31 | 72.94% | $63.78 Million | $87.44 Million | +6.00pp |
| 2008-12-31 | 66.94% | $45.42 Million | $67.85 Million | -15.07pp |
| 2007-12-31 | 82.02% | $68.81 Million | $83.90 Million | +8.12pp |
| 2006-12-31 | 73.89% | $41.22 Million | $55.78 Million | +15.81pp |
| 2005-12-31 | 58.08% | $28.45 Million | $48.98 Million | -12.86pp |
| 2004-12-31 | 70.94% | $24.63 Million | $34.73 Million | -2.71pp |
| 2003-12-31 | 73.65% | $34.05 Million | $46.23 Million | +12.29pp |
| 2002-12-31 | 61.37% | $34.50 Million | $56.23 Million | -2.09pp |
| 2001-12-31 | 63.46% | $53.95 Million | $85.02 Million | -13.96pp |
| 2000-12-31 | 77.42% | $53.36 Million | $68.92 Million | -1.93pp |
| 1999-12-31 | 79.35% | $7.30 Million | $9.20 Million | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more